Retina Foundation of the Southwest

Dallas, Texas 75382

21 studies enrolling now · 86 studies all time

What they study most

AMD, ARB, Age Related Macular Degeneration, Age-Related Macular Degeneration, Age-related Macular Degeneration (AMD), Allergy, Amblyopia, Asthma, Autosomal Dominant Retinitis Pigmentosa, Autosomal-Dominant Bestrophinopathy, BVMD, Best Vitelliform Macular Dystrophy

Studies at this site

• ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis — Recruiting now
• A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults — Recruiting now
• A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) — Recruiting now
• Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants — Recruiting now
• A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) — Recruiting now
• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy — Recruiting now
• Study of ALK-001 on the Progression of Stargardt Disease — Recruiting now
• A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) — Recruiting now
• Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants — Recruiting now
• An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA) — Recruiting now
• Improving Control of Intermittent Exotropia — Recruiting now
• Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID) — Recruiting now
• Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) — Recruiting now
• Binocular Amblyopia Treatment — Recruiting now
• Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients — Recruiting now
• A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration — Recruiting now
• Amblyopia Treatment for Children Aged 8 to 12 Years — Recruiting now
• Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) — Recruiting now
• An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene — Recruiting now
• A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) — Recruiting now
• Rate of Progression in EYS Related Retinal Degeneration — Completed
• A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa — Running, not enrolling
• A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease — Running, not enrolling
• A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy — Running, not enrolling
• Rate of Progression in USH2A-related Retinal Degeneration — Running, not enrolling
• Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene — Running, not enrolling
• Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa — Completed
• A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa — Running, not enrolling
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
• An Observational Study in Children and Adults With Stargardt Disease — Running, not enrolling
• Oral N-acetylcysteine for Retinitis Pigmentosa — Running, not enrolling
• A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 — Running, not enrolling
• MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) — Completed
• SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects — Completed
• Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy — Completed
• Promising ROd-cone DYstrophy Gene therapY — Running, not enrolling
• A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy — Running, not enrolling
• A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Running, not enrolling
• Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) — Completed
• Natural History of PRPF31 Mutation-Associated Retinal Dystrophy — Running, not enrolling
• A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP — Running, not enrolling
• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Completed
• HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 — Stopped early
• A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) — Running, not enrolling
• A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) — Completed
• A Study of NGM621 in Participants With Geographic Atrophy — Completed
• Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia — Running, not enrolling
• Binocular iPad Sub-Study — Running, not enrolling
• 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) — Running, not enrolling
• A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) — Enrolling by invitation